FY2025 · ended Dec 31, 2025 · Revenue $7.76M, -56.3% YoY · Filed Mar 4, 2026
Biolargo, Inc. (BLGO) files with the SEC under industry code 2800, Chemicals & Allied Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.8 million and a net loss of $15.2 million. As of Jun 30, 2026 it held $2.2 million in cash and investments and $1.3 million in total debt.
Revenue (TTM)
$4.08M
-71.0% vs year-ago TTM
Net income (TTM)
$-18.79M
-184.9% vs year-ago TTM
Operating cash flow (TTM)
$-10.32M
-37.9% vs year-ago TTM
Free cash flow
$-4.31M
EPS
—
Dividend per share
None
Shares outstanding
320.88M
+0.4% vs prior year
Net cash
$900,000
as of Jun 30, 2026
Operating margin
-443.9%
FY 2026
Company profile
- Industry
- Chemicals & Allied Products (SIC 2800)
- Listed as
- BLGO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westminster, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 880242
- Former names
- NUWAY MEDICAL INC (until Apr 3, 2007); NUWAY ENERGY INC (until Feb 5, 2003); LATIN AMERICAN CASINOS INC (until Feb 15, 2001)
Other Chemicals & Allied Products companies
- Akzo Nobel NV AKZOY
- Solstice Advanced Materials Inc. SOLS
- Balchem Corp BCPC
- Perimeter Solutions, Inc. PRM
- Ingevity Corp NGVT
- Innospec Inc. IOSP
- Chemours Co CC
- OLIN Corp OLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.8M | $17.8M | $12.2M | $5.9M | $2.5M |
| Operating income | -$14.9M | -$4.3M | -$4.6M | -$5.4M | -$6.8M |
| Net income | -$15.2M | -$4.3M | -$4.6M | -$5.1M | -$6.9M |
| Operating cash flow | -$8.3M | -$3.2M | -$2.4M | -$2.8M | -$3.9M |
| Total assets | $8.3M | $10.5M | $8.2M | $4.9M | $3.0M |
| Total liabilities | $6.8M | $4.5M | $4.0M | $2.8M | $2.1M |
| Stockholders' equity | $4.0M | $8.9M | $6.8M | $4.9M | $4.7M |
| Cash and investments | $3.9M | $3.5M | $3.5M | $1.9M | $962,000 |
| Total debt | $3.5M | $2.6M | $1.5M | $1.2M | $946,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K/A |
Amended current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 6, 2026 | May 5, 2026 |
All 1000 Biolargo, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.